Literature DB >> 23480694

Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.

Jan B Egan, K Martin Kortuem, Ahmet Kurdoglu, Tyler Izatt, Jessica Aldrich, Rebecca Reiman, Lori Phillips, Angela Baker, Chang-Xin Shi, Jessica Schmidt, Winnie S Liang, David W Craig, John D Carpten, A Keith Stewart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23480694      PMCID： PMC3655110          DOI： 10.1111/bjh.12291

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA.

Authors:  P A Moalli; S Pillay; D Weiner; R Leikin; S T Rosen
Journal:  Blood       Date:  1992-01-01       Impact factor: 22.113

2.  A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes.

Authors:  Yuko Hirano; Klavs B Hendil; Hideki Yashiroda; Shun-ichiro Iemura; Ryoichi Nagane; Yusaku Hioki; Tohru Natsume; Keiji Tanaka; Shigeo Murata
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

3.  Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

Authors:  Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; Laura A Bruins; Jessica E Schmidt; Scott Van Wier; Xiu-Bao Chang; Chad C Bjorklund; Rafael Fonseca; P Leif Bergsagel; Robert Z Orlowski; A Keith Stewart
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

Review 4.  Targeting the PI3K signaling pathway in cancer therapy.

Authors:  Chandra Bartholomeusz; Ana Maria Gonzalez-Angulo
Journal:  Expert Opin Ther Targets       Date:  2012-01-12       Impact factor: 6.902

5.  PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Authors:  Filip Janku; Jennifer J Wheler; Aung Naing; Gerald S Falchook; David S Hong; Vanda M Stepanek; Siqing Fu; Sarina A Piha-Paul; J Jack Lee; Rajyalakshmi Luthra; Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  Cancer Res       Date:  2012-10-12       Impact factor: 12.701

Review 6.  Variations of the human glucocorticoid receptor gene (NR3C1): pathological and in vitro mutations and polymorphisms.

Authors:  Paula J Bray; Richard G H Cotton
Journal:  Hum Mutat       Date:  2003-06       Impact factor: 4.878

7.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

8.  Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.

Authors:  Christoph J Heuck; Jackie Szymonifka; Emily Hansen; John D Shaughnessy; Saad Z Usmani; Frits van Rhee; Elias Anaissie; Bijay Nair; Sarah Waheed; Yazan Alsayed; Nathan Petty; Clyde Bailey; Joshua Epstein; Antje Hoering; John Crowley; Bart Barlogie
Journal:  Clin Cancer Res       Date:  2012-08-01       Impact factor: 12.531

9.  Initial genome sequencing and analysis of multiple myeloma.

Authors:  Michael A Chapman; Michael S Lawrence; Jonathan J Keats; Kristian Cibulskis; Carrie Sougnez; Anna C Schinzel; Christina L Harview; Jean-Philippe Brunet; Gregory J Ahmann; Mazhar Adli; Kenneth C Anderson; Kristin G Ardlie; Daniel Auclair; Angela Baker; P Leif Bergsagel; Bradley E Bernstein; Yotam Drier; Rafael Fonseca; Stacey B Gabriel; Craig C Hofmeister; Sundar Jagannath; Andrzej J Jakubowiak; Amrita Krishnan; Joan Levy; Ted Liefeld; Sagar Lonial; Scott Mahan; Bunmi Mfuko; Stefano Monti; Louise M Perkins; Robb Onofrio; Trevor J Pugh; S Vincent Rajkumar; Alex H Ramos; David S Siegel; Andrey Sivachenko; A Keith Stewart; Suzanne Trudel; Ravi Vij; Douglas Voet; Wendy Winckler; Todd Zimmerman; John Carpten; Jeff Trent; William C Hahn; Levi A Garraway; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub
Journal:  Nature       Date:  2011-03-24       Impact factor: 49.962

10.  Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.

Authors:  Brian A Walker; Christopher P Wardell; Lorenzo Melchor; Sanna Hulkki; Nicola E Potter; David C Johnson; Kerry Fenwick; Iwanka Kozarewa; David Gonzalez; Christopher J Lord; Alan Ashworth; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2012-05-09       Impact factor: 22.113
  10 in total
  29 in total

Review 1.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

2.  CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.

Authors:  Chang-Xin Shi; K Martin Kortüm; Yuan Xiao Zhu; Laura A Bruins; Patrick Jedlowski; Patrick G Votruba; Moulun Luo; Robert A Stewart; Jonathan Ahmann; Esteban Braggio; A Keith Stewart
Journal:  Mol Cancer Ther       Date:  2017-09-27       Impact factor: 6.261

3.  Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.

Authors:  S Mithraprabhu; T Khong; M Ramachandran; A Chow; D Klarica; L Mai; S Walsh; D Broemeling; A Marziali; M Wiggin; J Hocking; A Kalff; B Durie; A Spencer
Journal:  Leukemia       Date:  2016-11-30       Impact factor: 11.528

4.  Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).

Authors:  K M Kortüm; C Langer; J Monge; L Bruins; Y X Zhu; C X Shi; P Jedlowski; J B Egan; J Ojha; L Bullinger; M Kull; G Ahmann; L Rasche; S Knop; R Fonseca; H Einsele; A K Stewart; Esteban Braggio
Journal:  Ann Hematol       Date:  2015-03-07       Impact factor: 3.673

5.  Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Authors:  N Bolli; G Biancon; M Moarii; S Gimondi; Y Li; C de Philippis; F Maura; V Sathiaseelan; Y-T Tai; L Mudie; S O'Meara; K Raine; J W Teague; A P Butler; C Carniti; M Gerstung; T Bagratuni; E Kastritis; M Dimopoulos; P Corradini; K Anderson; P Moreau; S Minvielle; P J Campbell; E Papaemmanuil; H Avet-Loiseau; N C Munshi
Journal:  Leukemia       Date:  2017-12-06       Impact factor: 11.528

Review 6.  Extramedullary multiple myeloma.

Authors:  Manisha Bhutani; David M Foureau; Shebli Atrash; Peter M Voorhees; Saad Z Usmani
Journal:  Leukemia       Date:  2019-11-27       Impact factor: 11.528

7.  CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.

Authors:  Matteo Claudio Da Vià; Antonio Giovanni Solimando; Andoni Garitano-Trojaola; Santiago Barrio; Umair Munawar; Susanne Strifler; Larissa Haertle; Nadine Rhodes; Eva Teufel; Cornelia Vogt; Constantin Lapa; Andreas Beilhack; Leo Rasche; Hermann Einsele; K Martin Kortüm
Journal:  Oncologist       Date:  2019-10-18

Review 8.  Staging and prognostication of multiple myeloma.

Authors:  Rafael Fonseca; Jorge Monge; Meletios A Dimopoulos
Journal:  Expert Rev Hematol       Date:  2014-02       Impact factor: 2.929

9.  Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.

Authors:  Bachisio Ziccheddu; Giulia Biancon; Filippo Bagnoli; Chiara De Philippis; Francesco Maura; Even H Rustad; Matteo Dugo; Andrea Devecchi; Loris De Cecco; Marialuisa Sensi; Carolina Terragna; Marina Martello; Tina Bagratuni; Efstathios Kastritis; Meletios A Dimopoulos; Michele Cavo; Cristiana Carniti; Vittorio Montefusco; Paolo Corradini; Niccolo Bolli
Journal:  Blood Adv       Date:  2020-03-10

10.  Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

Authors:  K Martin Kortüm; Elias K Mai; Nur H Hanafiah; Chang-Xi Shi; Yuan-Xiao Zhu; Laura Bruins; Santiago Barrio; Patrick Jedlowski; Maximilian Merz; Jing Xu; Robert A Stewart; Mindaugas Andrulis; Anna Jauch; Jens Hillengass; Hartmut Goldschmidt; P Leif Bergsagel; Esteban Braggio; A Keith Stewart; Marc S Raab
Journal:  Blood       Date:  2016-07-25       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.